Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19.7M
-
Number of holders
-
260
-
Total 13F shares, excl. options
-
25M
-
Shares change
-
+685K
-
Total reported value, excl. options
-
$3.04B
-
Value change
-
+$88.1M
-
Put/Call ratio
-
0.14
-
Number of buys
-
136
-
Number of sells
-
-107
-
Price
-
$121.40
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q2 2017
299 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q2 2017.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 260 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25M shares
.
Largest 10 shareholders include BlackRock Inc. (2.68M shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (1.77M shares), VANGUARD GROUP INC (1.74M shares), Knott David M (998K shares), STATE STREET CORP (812K shares), CARDINAL CAPITAL MANAGEMENT LLC /CT (801K shares), SCOPIA CAPITAL MANAGEMENT LP (729K shares), VICTORY CAPITAL MANAGEMENT INC (679K shares), JANUS HENDERSON GROUP PLC (595K shares), and DEUTSCHE BANK AG\ (571K shares).
This table shows the top 260 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.